• +1-646-491-9876
    • +91-20-67278686

    Search

    B-Cell Chronic Lymphocytic Leukemia-Pipeline Review H2 2017

    B-Cell Chronic Lymphocytic Leukemia-Pipeline Review H2 2017

    • Report Code ID: RW00011022663
    • Category Life Sciences
    • No. of Pages 174
    • Publication Month Aug-17
    • Publisher Name Global Markets Direct
    B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H2 2017

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H2 2017, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape.

    B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 12, 7, 11 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively.

    B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology).
    -The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Global Markets Direct Report Coverage 7
    B-Cell Chronic Lymphocytic Leukemia-Overview 8
    B-Cell Chronic Lymphocytic Leukemia-Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 14
    Products under Development by Universities/Institutes 16
    B-Cell Chronic Lymphocytic Leukemia-Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 23
    Assessment by Molecule Type 25
    B-Cell Chronic Lymphocytic Leukemia-Companies Involved in Therapeutics Development 27
    AB Science SA 27
    Aduro BioTech Inc 27
    BioInvent International AB 28
    Boehringer Ingelheim GmbH 28
    Celgene Corp 29
    Cell Source Inc 29
    Cellectis SA 30
    Dynavax Technologies Corp 30
    Elsalys Biotech SAS 31
    F. Hoffmann-La Roche Ltd 31
    iDD biotech SAS 32
    Immunomedics Inc 32
    Johnson & Johnson 33
    Juno Therapeutics Inc 33
    Lymphocyte Activation Technologies SA 34
    Mabion SA 34
    MedImmune LLC 35
    MEI Pharma Inc 35
    Millennium Pharmaceuticals Inc 36
    Molecular Templates Inc 36
    Novartis AG 37
    Noxxon Pharma AG 37
    Ono Pharmaceutical Co Ltd 38
    Portola Pharmaceuticals Inc 38
    Regeneron Pharmaceuticals Inc 39
    Sunesis Pharmaceuticals Inc 39
    TheraMAB LLC 40
    Unum Therapeutics Inc 40
    B-Cell Chronic Lymphocytic Leukemia-Drug Profiles 41
    202-b-Drug Profile 41
    2X-121-Drug Profile 43
    AB-8779-Drug Profile 45
    alemtuzumab biosimilar-Drug Profile 46
    alisertib-Drug Profile 47
    BI-1206-Drug Profile 53
    BI-836826-Drug Profile 55
    BION-1301-Drug Profile 57
    Cellular Immunotherapy for Chronic Lymphocytic Leukaemia-Drug Profile 59
    Cellular Immunotherapy for Hematological Malignancies-Drug Profile 60
    Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies-Drug Profile 61
    Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies-Drug Profile 63
    Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies-Drug Profile 65
    Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia-Drug Profile 67
    Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia-Drug Profile 68
    Cellular Immunotherapy to Target CD19 for B-Cell Malignancies-Drug Profile 69
    Cellular Immunotherapy to Target CD19 for Oncology-Drug Profile 70
    Cellular Immunotherapy to Target CD19 for Oncology-Drug Profile 71
    Cellular Immunotherapy to Target CD19 for Oncology-Drug Profile 72
    cerdulatinib-Drug Profile 73
    DTRMWXHS-12-Drug Profile 77
    durvalumab-Drug Profile 78
    duvortuxizumab-Drug Profile 95
    ELB-021-Drug Profile 97
    IDD-001-Drug Profile 98
    IDD-002-Drug Profile 99
    lenalidomide-Drug Profile 100
    ME-401-Drug Profile 117
    mRNA ACTR + rituximab-Drug Profile 119
    MT-3724-Drug Profile 121
    olaptesed pegol-Drug Profile 124
    REGN-1979-Drug Profile 129
    rituximab biosimilar-Drug Profile 130
    SD-101-Drug Profile 132
    SNS-062-Drug Profile 137
    TAB-08-Drug Profile 140
    tirabrutinib-Drug Profile 143
    tisagenlecleucel-T-Drug Profile 146
    tocilizumab-Drug Profile 154
    UCART-22-Drug Profile 164
    UCARTCS-1-Drug Profile 165
    B-Cell Chronic Lymphocytic Leukemia-Dormant Projects 166
    B-Cell Chronic Lymphocytic Leukemia-Discontinued Products 168
    B-Cell Chronic Lymphocytic Leukemia-Product Development Milestones 169
    Featured News & Press Releases 169
    Appendix 171
    Methodology 171
    Coverage 171
    Secondary Research 171
    Primary Research 171
    Expert Panel Validation 171
    Contact Us 171
    Disclaimer 172

    List of Tables
    Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by AB Science SA, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Aduro BioTech Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by BioInvent International AB, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Boehringer Ingelheim GmbH, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Celgene Corp, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Cell Source Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Cellectis SA, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Dynavax Technologies Corp, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Elsalys Biotech SAS, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by iDD biotech SAS, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Immunomedics Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Johnson & Johnson, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Juno Therapeutics Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Lymphocyte Activation Technologies SA, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Mabion SA, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by MedImmune LLC, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by MEI Pharma Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Millennium Pharmaceuticals Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Molecular Templates Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Novartis AG, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Noxxon Pharma AG, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Portola Pharmaceuticals Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Sunesis Pharmaceuticals Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by TheraMAB LLC, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Pipeline by Unum Therapeutics Inc, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Dormant Projects, H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Dormant Projects, H2 2017 (Contd..1), H2 2017
    B-Cell Chronic Lymphocytic Leukemia-Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Top 10 Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    AB Science SA
    Aduro BioTech Inc
    BioInvent International AB
    Boehringer Ingelheim GmbH
    Celgene Corp
    Cell Source Inc
    Cellectis SA
    Dynavax Technologies Corp
    Elsalys Biotech SAS
    F. Hoffmann-La Roche Ltd
    iDD biotech SAS
    Immunomedics Inc
    Johnson & Johnson
    Juno Therapeutics Inc
    Lymphocyte Activation Technologies SA
    Mabion SA
    MedImmune LLC
    MEI Pharma Inc
    Millennium Pharmaceuticals Inc
    Molecular Templates Inc
    Novartis AG
    Noxxon Pharma AG
    Ono Pharmaceutical Co Ltd
    Portola Pharmaceuticals Inc
    Regeneron Pharmaceuticals Inc
    Sunesis Pharmaceuticals Inc
    TheraMAB LLC
    Unum Therapeutics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//b-cell-chronic-lymphocytic-leukemia-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//b-cell-chronic-lymphocytic-leukemia-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//b-cell-chronic-lymphocytic-leukemia-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments